ISRCTN79981540已完成未知
Early treatment with molnupiravir in the elderly at risk for Covid-19
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 29
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 性别
- All
入选标准
- •1. Over 80 years of age
- •2. At least one risk factor of: age >60 years, active cancer, chronic kidney disease, chronic obstructive pulmonary disease, obesity defined by a body-mass index (the weight in kilograms divided by the square of the height in meters) =30, serious heart conditions (heart failure, coronary artery disease, or cardiomyopathies), diabetes mellitus, according to the guidance of Food and Drug Administration and World Health Organization (WHO)
排除标准
- •1. The use of dialysis
- •2. Estimated glomerular filtration rate of 30 ml/minute/1.73 m² or less
- •3. Pregnancy
- •4. Neutropenia (neutrophil count of <500 / ml)
- •5. Platelet count <100,000/microliter
- •6. Monoclonal antibodies
- •7. Remdesivir
研究者
相似试验
尚未招募
3 期
The Therapeutic Effect of Molnupiravir in COVID-19 PatientsIRCT20210901052358N1Shahid Beheshti University of Medical Sciences60
已完成
2 期
A Study of Clofarabine in Older Patients With Acute Myeloid Leukemia (AML) for Whom Chemotherapy Is Not SuitableAcute Myeloid LeukemiaNCT00924443Genzyme, a Sanofi Company69
终止
2 期
Efficacy and Safety of Molnupiravir (MK-4482) in Hospitalized Adult Participants With COVID-19 (MK-4482-001)Coronavirus Disease (COVID-19)NCT04575584Merck Sharp & Dohme LLC304
已完成
2 期
Efficacy and Safety of Molnupiravir (MK-4482) in Non-Hospitalized Adult Participants With COVID-19 (MK-4482-002)Coronavirus Disease (COVID-19)NCT04575597Merck Sharp & Dohme LLC1,735
进行中（未招募）
1 期
A PHASE II TRIAL OF CLOFARABINE IN OLDER PATIENTS WITH ACUTE MYELOID LEUKAEMIA FOR WHOM INTENSIVE CHEMOTHERAPY IS NOT CONSIDERED SUITABLEEUCTR2004-004527-35-IEBioenvision Limited65